Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis
Executive Summary
Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?
You may also be interested in...
Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema
A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.
CHMP Delivers More Good News For Sanofi's Dupixent
The European committee has adopted a positive opinion for Regeneron-partnered Dupixent recommending approval to include adolescents aged 12 to 17 with atopic dermatitis.